KRMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Karman Holdings Inc (KRMN) is a good buy for a long-term beginner investor with $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and favorable long-term growth prospects in the defense sector outweigh the minor technical weakness and lack of immediate trading signals.
The MACD is negative and expanding (-0.571), indicating bearish momentum. RSI is at 25.676, suggesting the stock is oversold but not yet signaling a reversal. Moving averages are converging, indicating a lack of clear trend direction. The stock is trading below its pivot level (84.917) and close to its first support level (77.818), which could act as a near-term floor.
Strong financial performance in Q4 2025, with a 47.41% YoY revenue increase and a 358.30% YoY net income increase.
Analysts are bullish, with multiple firms reiterating Buy/Outperform ratings and raising price targets (e.g., Citi at $127, Baird at $135).
The company is positioned to benefit from long-term defense spending trends, including a 'supercycle' in munitions and missile programs.
Positive sentiment from Evercore ISI regarding the procedural nature of the 10-K filing delay.
Pre-market price is down 0.69%, reflecting short-term bearish sentiment.
Technical indicators suggest bearish momentum with no immediate reversal signal.
BWS Financial maintains a Sell rating, citing concerns about free cash flow and a slight reduction in adjusted EBITDA margin guidance.
In Q4 2025, Karman Holdings reported a 47.41% YoY revenue increase to $134.49M, a 358.30% YoY net income increase to $7.71M, and a 500% YoY EPS increase to $0.06. Gross margin improved by 8.45% YoY to 32.72%. These figures indicate strong growth and operational efficiency.
Analysts are broadly positive on KRMN, with multiple Buy/Outperform ratings and price targets ranging from $122 to $135. The company is seen as well-positioned to capitalize on long-term defense spending trends. However, one analyst (BWS Financial) maintains a Sell rating with a $37 price target, citing concerns about free cash flow and adjusted EBITDA margin.
